IP Library Granted Patent US 12,465,697
Granted Patent B1
US 12,465,697 · App. 19/064,155 · Granted Nov 11, 2025

Medicament delivery device

Inventors: Alexander Hee-Hanson (Melbourn, GB); Thomas Lever (Melbourn, GB); Michael Parrott (Melbourn, GB); Robert Wilson (Melbourn, GB); Haiming Wu (Cambridge, MA)
Assignee: Genzyme Corporation
A61M5/3158A61M5/31536
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,465,697
App. No.
19/064,155
Granted
Nov 11, 2025
Kind
B1
Abstract

A medicament delivery device is described. The medicament delivery device includes a proximal end and a distal end defining a longitudinal axis; a body; and a button arranged at the proximal end and configured to actuate the medicament delivery device. The medicament delivery device further includes a lock ring configured to rotate relative to the body about the longitudinal axis between a first position in which the button is not permitted to move along the longitudinal axis relative to the body, and a second position in which the button is permitted to move along the longitudinal axis relative to the body; a plurality of first indication elements circumferentially spaced around a first portion of the medicament delivery device; and a plurality of second indication elements circumferentially spaced around a second portion of the medicament delivery device.

Claims (34)

1 . A medicament delivery device comprising:

a proximal end and a distal end defining a longitudinal axis;

a body;

a button arranged at the proximal end and configured to actuate the medicament delivery device;

a lock ring configured to rotate relative to the body about the longitudinal axis between a first position in which the button is not permitted to move along the longitudinal axis relative to the body, and a second position in which the button is permitted to move along the longitudinal axis relative to the body;

a plurality of first indication elements circumferentially spaced around a first portion of the medicament delivery device; and

a plurality of second indication elements circumferentially spaced around a second portion of the medicament delivery device,

wherein the plurality of first indication elements and the plurality of second indication elements are moveable relative to one another between a first state in which at least one first indication element of the plurality of first indication elements is not axially aligned with at least one second indication element of the plurality of second indication elements, and a second state in which said at least one first indication element of the plurality of first indication elements is axially aligned with said at least one second indication element of the plurality of second indication elements,

wherein the lock ring is configured such that when the lock ring is in the first position, the plurality of first indication elements and the plurality of second indication elements are in the first state, and when the lock ring is in the second position, the plurality of first indication elements and the plurality of second indication elements are in the second state, and

wherein the second portion of the medicament delivery device comprises an indicator ring, wherein the indicator ring and the first portion of the medicament delivery device are rotatable relative to one another, and wherein the indicator ring comprises the plurality of second indication elements which is circumferentially spaced apart around the indicator ring and is separated by a plurality of masking portions configured to mask the plurality of first indication elements, such that:

when the plurality of first indication elements and the plurality of second indication elements are in the first state, each first indication element of the plurality of first indication elements is aligned with a respective one of the plurality of masking portions, such that the plurality of first indication elements is not visible, and

when the plurality of first indication elements and the plurality of second indication elements are in the second state, each first indication element of the plurality of first indication elements is not aligned with a respective one of the plurality of masking portions, such that the plurality of first indication elements is visible.

2 . The medicament delivery device of claim 1 , wherein each first indication element of the plurality of first indication elements is configured to be axially alignable with a respective second indication element of the plurality of second indication elements.

3 . The medicament delivery device of claim 1 , wherein the button is coupled to the lock ring such that the button is configured to rotate relative to the body about the longitudinal axis together with the lock ring.

4 . The medicament delivery device of claim 1 , wherein the first portion comprises at least a portion of the lock ring such that the plurality of first indication elements is arranged on the lock ring, or

wherein the first portion comprises at least a portion of the button such that the plurality of first indication elements is arranged on the button.

5 . The medicament delivery device of claim 1 , wherein the plurality of first indication elements and/or the plurality of second indication elements comprises a visual indicator.

6 . The medicament delivery device of claim 5 , wherein the visual indicator is printed.

7 . The medicament delivery device of claim 1 , wherein the first portion comprises a first color, and wherein the plurality of first indication elements each comprises a second color that is different from the first color.

8 . The medicament delivery device of claim 7 , wherein the second portion further comprises a plurality of third indication elements, wherein when the plurality of first indication elements and the plurality of second indication elements are in the first state, at least one first indication element of the plurality of first indication elements is axially aligned with at least one third indication element of the plurality of third indication elements, and when the plurality of first indication elements and second indication elements are in the second state, said at least one first indication element of the plurality of first indication elements is not axially aligned with said at least one third indication element of the plurality of third indication elements.

9 . The medicament delivery device of claim 1 , wherein the plurality of first indication elements and/or the plurality of second indication elements comprises a tactile indicator.

10 . The medicament delivery device of claim 9 , wherein the tactile indicator comprises a portion that protrudes from and/or comprises a different surface texture than the remainder of the first portion or the second portion respectively.

11 . The medicament delivery device of claim 1 , wherein each of the plurality of second indication elements comprises a cut-out, gap, aperture, transparent portion or translucent portion of the indicator ring, and each of the plurality of masking portions comprises a solid and/or opaque portion of the indicator ring.

12 . The medicament delivery device of claim 1 , wherein the indicator ring is configured to circumscribe the first portion of the medicament delivery device.

13 . The medicament delivery device of claim 1 , wherein the button or the lock ring comprises the indicator ring.

14 . The medicament delivery device of claim 1 , wherein the plurality of first indication elements each comprises a first shape and are circumferentially spaced apart around the first portion separated by a plurality of spacing portions also comprising the first shape, to form a first circumferential pattern of alternating first indication elements and spacing portions, and

wherein the plurality of second indication elements and the plurality of masking portions comprise the first shape and form a second circumferential pattern of alternating second indication elements and masking portions, such that the second circumferential pattern corresponds with the first circumferential pattern.

15 . The medicament delivery device of claim 1 , wherein the button is arrangeable in an extended position in which a proximal portion of the button is arranged to protrude from the lock ring, and a retracted position in which the proximal portion of the button is arranged inside the lock ring,

wherein when the lock ring is in the first position the button is arranged in the extended position, and when the lock ring is in the second position the button is permitted to move along the longitudinal axis in a distal direction towards the distal end towards the retracted position, and

wherein the medicament delivery device further comprises:

a spring configured to bias the button towards the extended position, and

a spring guide configured to house and/or constrain the spring,

wherein the spring guide comprises the indicator ring and a main body configured to be received inside the lock ring, wherein the indicator ring is arranged to protrude from the main body, and wherein the plurality of first indication elements is arranged on an indicator portion of the button or the lock ring and the indicator ring is configured to circumscribe the indicator portion.

16 . The medicament delivery device of claim 1 , further comprising a medicament.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2025
From: PA HOLDING LIMITED
To: PA CONSULTING SERVICES LIMITED
Reel/Frame 072504/0470 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: WU, HAIMING
To: GENZYME CORPORATION
Reel/Frame 072139/0488 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: HEE-HANSON, ALEXANDER; PARROTT, MICHAEL; LEVER, THOMAS; WILSON, ROBERT
To: PA HOLDINGS LIMITED
Reel/Frame 072139/0512 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: PA CONSULTING SERVICES
To: SANOFI-AVENTIS DEUTSCHLAND GMBH
Reel/Frame 072139/0623 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 2, 2025
From: SANOFI-AVENTIS DEUTSCHLAND GMBH
To: GENZYME CORPORATION
Reel/Frame 072139/0648 →
References Cited (107)
US 2522961A · William · 1950 [cited by applicant]
US 2633267A · Lebus · 1953 [cited by applicant]
US 3886513A · Smith et al. · 1975 [cited by applicant]
US 4801295A · Spencer · 1989 [cited by applicant]
US 5045062A · Henson · 1991 [cited by applicant]
US 5176275A · Bowie · 1993 [cited by applicant]
US 5328484A · Somers et al. · 1994 [cited by applicant]
US 5396051A · Kuhn et al. · 1995 [cited by applicant]
US 5478316A · Bitdinger et al. · 1995 [cited by applicant]
US 5505324A · Danico · 1996 [cited by applicant]
US 5505706A · Maus et al. · 1996 [cited by applicant]
US 5536917A · Suppelsa et al. · 1996 [cited by applicant]
US 5622274A · Bright · 1997 [cited by applicant]
US 5738658A · Maus et al. · 1998 [cited by applicant]
US 5984899A · D'Alessio et al. · 1999 [cited by applicant]
US 6080461A · Wozniak et al. · 2000 [cited by applicant]
US 6394985B1 · Lin · 2002 [cited by applicant]
US 7762981B2 · Dacquay et al. · 2010 [cited by applicant]
US 7887506B1 · Smolyarov et al. · 2011 [cited by applicant]
US 7918824B2 · Bishop et al. · 2011 [cited by applicant]
US 8133198B2 · Neer · 2012 [cited by applicant]
US 8409138B2 · James et al. · 2013 [cited by applicant]
US 8734394B2 · Adams et al. · 2014 [cited by applicant]
US 9044553B2 · James et al. · 2015 [cited by applicant]
US 9402957B2 · Adams et al. · 2016 [cited by applicant]
US 9474780B2 · Bokvist et al. · 2016 [cited by applicant]
US 9872961B2 · Fourt et al. · 2018 [cited by applicant]
US 10118001B2 · Fourt et al. · 2018 [cited by applicant]
US 10314981B2 · Sampson et al. · 2019 [cited by applicant]
US 10350362B2 · Dennis, Jr. et al. · 2019 [cited by applicant]
US 10363377B2 · Atterbury et al. · 2019 [cited by applicant]
US 11298462B2 · Atterbury et al. · 2022 [cited by applicant]
US 11331432B2 · Holmqvist et al. · 2022 [cited by applicant]
US 11357820B2 · Corvari et al. · 2022 [cited by applicant]
US 11369751B2 · Ruan et al. · 2022 [cited by applicant]
US 11452821B2 · LaFever et al. · 2022 [cited by applicant]
US 20020055712A1 · Neracher · 2002 [cited by applicant]
US 20040039336A1 · Amark et al. · 2004 [cited by applicant]
US 20050101919A1 · Brunnberg · 2005 [cited by applicant]
US 20050273061A1 · Hommann et al. · 2005 [cited by applicant]
US 20060224124A1 · Scherer · 2006 [cited by applicant]
US 20070270777A1 · Dacquay et al. · 2007 [cited by applicant]
US 20080097311A1 · Dacquay et al. · 2008 [cited by applicant]
US 20080097390A1 · Dacquay et al. · 2008 [cited by applicant]
US 20080269692A1 · James et al. · 2008 [cited by applicant]
US 20090036868A1 · Pinedjian et al. · 2009 [cited by applicant]
US 20090281496A1 · Matusch · 2009 [cited by applicant]
US 20100049125A1 · James · 2010 [cited by examiner]
US 20100211005A1 · Edwards et al. · 2010 [cited by applicant]
US 20110054414A1 · Shang et al. · 2011 [cited by applicant]
US 20110144594A1 · Sund et al. · 2011 [cited by applicant]
US 20110202011A1 · Wozencroft · 2011 [cited by applicant]
US 20110319813A1 · Kamen et al. · 2011 [cited by applicant]
US 20120310172A1 · MacDonald · 2012 [cited by examiner]
US 20130237921A1 · Lannan et al. · 2013 [cited by applicant]
US 20130267897A1 · Kemp et al. · 2013 [cited by applicant]
US 20140236076A1 · Marshall et al. · 2014 [cited by applicant]
US 20140249483A1 · Kiilerich et al. · 2014 [cited by applicant]
US 20140263156A1 · Newsom et al. · 2014 [cited by applicant]
US 20140276637A1 · Massey, Jr. · 2014 [cited by applicant]
US 20150246180A1 · Fenlon et al. · 2015 [cited by applicant]
US 20150273162A1 · Holmqvist · 2015 [cited by applicant]
US 20160001015A1 · Kucuk et al. · 2016 [cited by applicant]
US 20160354555A1 · Gibson et al. · 2016 [cited by applicant]
US 20160367763A1 · Tschirren et al. · 2016 [cited by applicant]
US 20170215699A1 · Ouyang et al. · 2017 [cited by applicant]
US 20170216526A1 · Brereton et al. · 2017 [cited by applicant]
US 20170224929A1 · Sampson et al. · 2017 [cited by applicant]
US 20170246403A1 · Cowe et al. · 2017 [cited by applicant]
US 20170361034A1 · Scheller et al. · 2017 [cited by applicant]
US 20180250471A1 · Grimoldby et al. · 2018 [cited by applicant]
US 20180339114A1 · Wendland et al. · 2018 [cited by applicant]
US 20190030249A1 · Gonzalez et al. · 2019 [cited by applicant]
US 20190192785A1 · Wendland et al. · 2019 [cited by applicant]
US 20190298924A1 · Gibson · 2019 [cited by examiner]
US 20190366000A1 · Cowe et al. · 2019 [cited by applicant]
US 20200114041A1 · Alas et al. · 2020 [cited by applicant]
US 20200316314A1 · Buri et al. · 2020 [cited by applicant]
US 20210077732A1 · Egelhofer · 2021 [cited by applicant]
US 20210196900A1 · Apply et al. · 2021 [cited by applicant]
US 20220015429A1 · Brown et al. · 2022 [cited by applicant]
US 20220176042A1 · Belisle · 2022 [cited by applicant]
US 20220395640A1 · Schwartzentruber · 2022 [cited by applicant]
US 20230001099A1 · Dunn · 2023 [cited by applicant]
US 20230238105A1 · Schneider et al. · 2023 [cited by applicant]
US 20230347074A1 · Gavin · 2023 [cited by applicant]
US 20240009397A1 · In et al. · 2024 [cited by applicant]
US 20240307620A1 · Fiard · 2024 [cited by applicant]
US 20240335613A1 · Carrel · 2024 [cited by applicant]
DE 3921747A1 · 1991 [cited by applicant]
EP 3501577A1 · 2019 [cited by applicant]
WO WO2002047746A1 · 2002 [cited by applicant]
WO WO2004058820A2 · 2004 [cited by applicant]
WO WO2004068820A2 · 2004 [cited by applicant]
WO WO2005018629A1 · 2005 [cited by applicant]
WO WO2006003388A2 · 2006 [cited by applicant]
WO WO2006030220A1 · 2006 [cited by applicant]
WO WO2011109205A2 · 2011 [cited by applicant]
WO WO2016081238A1 · 2016 [cited by applicant]
WO WO2019074788A1 · 2019 [cited by applicant]
WO WO2020190529A1 · 2020 [cited by applicant]
Hamers-Casterman et al., “Naturally occurring antibodies devoid of light chains,” Nature, Jun. 3, 1993, 363(6428):446-448. [cited by applicant]
Holt et al., “Domain antibodies: proteins for therapy,” Trends in Biotechnology, Nov. 2003, 21(11):484-490. [cited by applicant]
Muyldermans, “Single domain camel antibodies: current status,” Reviews in Molecular Biotechnology, Jun. 2001, 74(4):277-302. [cited by applicant]
Needle-based injection systems for medical use requirements and test methods, Part 1: Needle injection systems, ISO 11608-1:2014(E), Third Edition, Switzerland, ISO, Dec. 15, 2014, pp. 1-13. [cited by applicant]
Ward et al., “Binding activities of a repertoire of single immunoglobulin variable domains secreted from [cited by applicant]
U.S. Appl. No. 19/064,414, filed Feb. 26, 2025, Alexander Hee-Hanson. [cited by applicant]
Cited By (1)
US 12,539,367